Abstract & Authors:展开
Despite major advances in pharmacological and device-based therapies, systemic hypertension (HTN) continues to be the major, modifiable risk factor for most cardiovascular disease and a leading cause of morbidity and mortality. Treatment resistant HTN (RH) is present in ≈15% to 20% of hypertensive patients, with few treatment options. These facts provide an opportunity to develop novel hypotheses to advance this field.
Carl J Pepine
YanFei Qi,Seungbum Kim,Elaine M Richards,Mohan K Raizada,Carl J Pepine